Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.2180
-0.0069 (-3.07%)
Streaming Delayed Price
Updated: 1:56 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM
October 31, 2022
Via
Investor Brand Network
Researchers Discover New Way to Noninvasively Monitor Immune Cells Inside Tumors
October 27, 2022
Via
Investor Brand Network
Patient Plays Sax During Lengthy Surgery to Remove Brain Tumor
October 20, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate
October 17, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment
October 14, 2022
Via
Investor Brand Network
Researchers Uncover Vital Clues on Drivers Behind Growth, Size of Brain Tumors
October 13, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run
October 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast
October 07, 2022
Via
Investor Brand Network
New Laws on Abortion May Complicate Cancer Treatment for Pregnant Patients
October 06, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients
October 03, 2022
Via
Investor Brand Network
Exposures
Product Safety
UC San Diego Offers New Radiation Therapy That Prevents Tumor Regrowth
September 30, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial
September 28, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event
September 23, 2022
Via
Investor Brand Network
Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs
September 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment
September 19, 2022
Via
Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM
September 16, 2022
Via
Investor Brand Network
Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
September 15, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
September 13, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
September 09, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
September 07, 2022
Via
Investor Brand Network
Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
September 07, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
September 01, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
August 30, 2022
Via
Investor Brand Network
Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
August 29, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
August 23, 2022
Via
Investor Brand Network
Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
August 19, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
August 15, 2022
Via
Investor Brand Network
Exposures
Product Safety
Researchers Want to Manage Cancer By Keeping Malignant Cells Restricted in Place
August 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success
August 12, 2022
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.